IMM · ASX

Immutep Ltd (ASX:IMM)

AU$0.36

 0.01 (2.899%)
ASX:Live
30/12/2024 04:10:27 PM
HALO Small HALO Ords HALO Momentum HALO Consensus Value GROWTH AUS +3
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

IMM Overview

IMM Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Very Strong

Valuation

Value

Consensus

Momentum

Price

Weak

Earnings

Weak

Growth

Earnings

Neutral

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Weak

About IMM

Website

Immutep Ltd

Telephone

61.2.8315.7003

Address

Level 32, Suite 32.07 264 George Street Australia Square Sydney, New South Wales (NSW) 2000

Description

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

IMM Price Chart

Key Stats

Market Cap

AU$487.62M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.23 - 0.48

Trade Value (12mth)

AU$299,610.00

1 week

2.99%

1 month

6.15%

YTD

0.92%

1 year

0.92%

All time high

4.07

Key Fundamentals

EPS 3 yr Growth

-27.30%

EBITDA Margin

N/A

Operating Cashflow

-$35m

Free Cash Flow Return

-21.20%

ROIC

-26.00%

Interest Coverage

-1,573.40

Quick Ratio

18.20

Other Data

Shares on Issue (Fully Dilluted)

1216m

HALO Sector

Healthcare

Next Company Report Date

27-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

2.15

IMM Announcements

Latest Announcements

Date Announcements

17 December 24

Immutep announces initial safety data from IMP761 phase 1

×

Immutep announces initial safety data from IMP761 phase 1

17 December 24

Notification of cessation of securities - IMM

×

Notification of cessation of securities - IMM

16 December 24

Publication Detailing How Human LAG-3 Binds to MHC Class II

×

Publication Detailing How Human LAG-3 Binds to MHC Class II

13 December 24

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

12 December 24

Immutep Reports Promising New Data in Head and Neck Cancer

×

Immutep Reports Promising New Data in Head and Neck Cancer

10 December 24

Initiation of TACTI-004 phase 3 trial in 1st line NSCLC

×

Initiation of TACTI-004 phase 3 trial in 1st line NSCLC

10 December 24

Change of Director's Interest Notice - M Voigt

×

Change of Director's Interest Notice - M Voigt

10 December 24

Change of Director's Interest Notice - F Triebel

×

Change of Director's Interest Notice - F Triebel

10 December 24

Change of Director's Interest Notice - R Howard

×

Change of Director's Interest Notice - R Howard

10 December 24

Change of Director's Interest Notice - L Boyce

×

Change of Director's Interest Notice - L Boyce

06 December 24

Application for quotation of securities - IMM

×

Application for quotation of securities - IMM

05 December 24

Notification regarding unquoted securities - IMM

×

Notification regarding unquoted securities - IMM

26 November 24

Immutep Investor Update

×

Immutep Investor Update

22 November 24

Immutep AGM 2024 - Chairman's Address

×

Immutep AGM 2024 - Chairman's Address

22 November 24

Immutep AGM 2024 - CEO's Presentation

×

Immutep AGM 2024 - CEO's Presentation

22 November 24

Results of Meeting

×

Results of Meeting

18 November 24

Change in substantial holding

×

Change in substantial holding

14 November 24

Becoming a substantial holder

×

Becoming a substantial holder

14 November 24

Positive Data from Phase II Trial in Soft Tissue Sarcoma

×

Positive Data from Phase II Trial in Soft Tissue Sarcoma

14 November 24

Excellent Survival Data from INSIGHT-003 Trial in NSCLC

×

Excellent Survival Data from INSIGHT-003 Trial in NSCLC

29 October 24

Immutep Quarterly Activities Report and Appendix 4C

×

Immutep Quarterly Activities Report and Appendix 4C

28 October 24

TACTI-003 Cohort B data to be presented at ESMO I-O

×

TACTI-003 Cohort B data to be presented at ESMO I-O

23 October 24

Annual Report filed on Form 20-F with SEC

×

Annual Report filed on Form 20-F with SEC

22 October 24

Annual Report to shareholders

×

Annual Report to shareholders

22 October 24

Appendix 4G and Corporate Governance Statement

×

Appendix 4G and Corporate Governance Statement

IMM Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.04 -0.04 Lock Lock Lock
     Growth % Lock Lock Lock Lock 24.5 -19.7 19.6 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.03 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.04 -0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -58.2 6.6 11.4 Lock Lock Lock
     Yield % Lock Lock Lock Lock -12.3 -12.6 -9.8 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.11 0.11 0.13 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.09 0.11 0.12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 19.4 12.7 17.8 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 870 901 1,201 Lock Lock Lock
Basic m Lock Lock Lock Lock 870 901 1,201 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -100.0 N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 36 43 48 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock -2 -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock 8.6 -8.9 -9.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -1,111.2 N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 1,211 0 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -36 -43 -48 Lock Lock Lock
     Growth % Lock Lock Lock Lock -69.3 -18.1 -12.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock -21,317.2 N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 2 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -38 -45 -50 Lock Lock Lock
     Growth % Lock Lock Lock Lock -63.2 -17.1 -12.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -22,528.4 N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -32 -40 -43 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -32 -40 -43 Lock Lock Lock
     Growth % Lock Lock Lock Lock -7.7 -23.9 -7.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -18,906.5 N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -30 -35 -35 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 1 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 0 -21 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 50 76 95 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -30 -35 -35 Lock Lock Lock
     Growth % Lock Lock Lock Lock -71.3 -17.1 1.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock -177.6 N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 80 123 182 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 102 147 202 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 2 1 1 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -78 -122 -180 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 8 11 12 Lock Lock Lock
Equity $m Lock Lock Lock Lock 94 136 190 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 96 138 191 Lock Lock Lock
     Growth % Lock Lock Lock Lock 26.0 43.8 38.8 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -31.5 -27.1 -21.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.2 -29.2 -22.5 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -44.7 -38.5 -30.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -37.6 -34.2 -26.0 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -35.2 -30.3 -21.2 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock -392.9 -2,101.6 -1,573.4 Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.2 2.8 3.7 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -83.2 -89.5 -95.1 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 14.2 13.8 18.2 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 14.2 13.8 18.2 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 88.1 91.4 95.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -471.3 -361.8 -332.1 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 1,682.3 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -18,906.5 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -31.5 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -31.5 -27.1 -21.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.1 1.1 1.1 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.2 -29.2 -22.5 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -34.2 -29.2 -22.5 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 15,530.4 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 15,530.4 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 414.9 735.9 745.4 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 15,115.5 -735.9 -745.4 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

2.15%

Value ($M)

11

Prior Change

N/A

7 Day Change

-0.10%

1 Month Change

0.20%

3 Month Change

1.00%

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

IMM Shortsell

Frequently Asked Questions

The current share price of Immutep Ltd (IMM:ASX) is AU$0.36.
The 52-week high share price for Immutep Ltd (IMM:ASX) is AU$0.48.
The 52-week low share price for Immutep Ltd (IMM:ASX)? is AU$0.23.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) does not pay a dividend.
Immutep Ltd (IMM:ASX) has a franking level of 0.0%.
Immutep Ltd (IMM:ASX) is classified in the Healthcare.
The current P/E ratio for Immutep Ltd (IMM:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.